HK Stock Market Move | GALAXY ENT (00027) rose by more than 3%. Adjusted EBITDA for the third quarter increased by 6% year-on-year to HK$2.9 billion.
Galaxy Entertainment (00027) rose more than 3%, as of the publication, it rose by 3.03%, closing at 35.65 Hong Kong dollars, with a turnover of 55.9348 million Hong Kong dollars.
GALAXY ENT (00027) rose more than 3%, closing at a 3.03% increase to 35.65 Hong Kong dollars, with a trading volume of 559.348 million Hong Kong dollars as of the time of this report.
In terms of news, GALAXY ENT announced this morning that for the third quarter ending on September 30, 2024, the group's net income was 10.7 billion Hong Kong dollars, an 11% year-on-year increase but a 2% decrease from the previous quarter; the group's adjusted EBITDA was 2.9 billion Hong Kong dollars, a 6% year-on-year increase but a 7% decrease from the previous quarter; the low net win rate in the gaming business led to a decrease of approximately 165 million Hong Kong dollars in adjusted EBITDA. After normalizing the net win rate, the adjusted EBITDA for the third quarter was 3.1 billion Hong Kong dollars, a 7% year-on-year increase but a 3% decrease from the previous quarter; the adjusted EBITDA for the past twelve months was 11.8 billion Hong Kong dollars, a 68% year-on-year increase and a 1% increase from the previous quarter.
Related Articles

SDHG (00412) responds to the concentration of equity, stating that the company is able to comply with the regulations on public shareholding requirements.

EVER REACH GP (03616) has reached the resumption guidance and will resume trading on September 19th.

IRC (01029) completes the sale of a 46% stake in the joint venture company.
SDHG (00412) responds to the concentration of equity, stating that the company is able to comply with the regulations on public shareholding requirements.

EVER REACH GP (03616) has reached the resumption guidance and will resume trading on September 19th.

IRC (01029) completes the sale of a 46% stake in the joint venture company.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025